Multicenter, USA - 04 Apr `17Incyte: A Study of Ruxolitinib 1,5% cream

Official Title: A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

In Brief: The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Description: Ruxolitinib cream 1.5% twice-daily for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension

Details: Check Incyte announcement or download pdf with a scientific presentation from UMass.

Ages Eligible: 18 Years to 75 Years

Start Date: April 19, 2017

Completion Date (estimated): September 2021

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03099304
Other Study ID Numbers: INCB 18424-211 

Location: 26 locations across the United States

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • Which diseases most commonly accompany vitiligo?

    According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...

  • Shall I take vitamin D for my vitiligo?

    In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...